At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
NT-501 CNTF implantcombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II, Multicenter, Open-label Safety Study of Bilateral NT-501 in Participants With Macular Telangiectasia Type 2
In Brief
A Phase 2 clinical trial evaluating NT-501 CNTF implant for Macular Telangiectasia Type 2. Completed, enrolled 33 participants across 10 sites in 2 countries.
Detailed Summary
This is a multi-center, open-label, 6-month study to evaluate the safety of bilateral CNTF implants in participants with Macular Telangiectasia Type 2.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Telangiectasia Type 2
CountriesAustralia, United States
CollaboratorsThe Lowy Medical Research Institute Limited
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartJul 2021
Primary CompletionDec 2022
TodayJul 2026
First PostedJan 29, 2021
Enrollment StartJul 21, 2021
Primary CompletionDec 8, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.4 years ago
Interventions
NT-501 CNTF implantcombination
Single implantation of CNTF-secreting NT-501 device into fellow (untreated) eye